Kimia Biosciences share news, announcements and annual reports
BSE: 530313Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 29 Oct 2026. Previous close ₹30.25.
29 Oct: open ₹30.00, high ₹30.90, low ₹30.00
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹144 Cr2,580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 20.05
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 8.13
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 51.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.95
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2
Kimia Biosciences share news and announcements
546 announcements, routine notices left out, newest first. Page 3 of 11.
Feb 2025
21 Feb · Non-Applicability Of Corporate Governance Report As Per Regulation 27(2) Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015 Pursuant To Regulation 15 Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015.
13 Feb · Results
7 Feb · Board meeting
Meeting on 13 Feb 2025: quarterly results
Jan 2025
22 Jan · Regulation 13(3) For The Statement Of Investor Complaints
Dec 2024
31 Dec · Meeting
30 Dec
13 Dec
11 Dec · Meeting
9 Dec · Meeting
7 Dec · Meeting
6 Dec · Board meeting
2 Dec · Board meeting
Meeting on 5 Dec 2024: annual general meeting
Nov 2024
14 Nov · Results
14 Nov · Management
12 Nov · Board meeting
Meeting on 14 Nov 2024: quarterly results
Sep 2024
Aug 2024
9 Aug · Intimation Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 For Filing Of Quality Product For Benfotiamine In European Union- Bulgaria.
6 Aug · Board meeting
Meeting on 14 Aug 2024: quarterly results
Jun 2024
28 Jun · Information Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements), Regulations 2015.
24 Jun · Board meeting
Meeting on 28 Jun 2024
May 2024
21 May · Board meeting
Meeting on 30 May 2024: audited results